Cinalukast [Usan-Inn]: Full Drug Profile

Cinalukast [Usan-Inn] - General Information

Used in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Cinalukast [Usan-Inn] inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.

Pharmacology of Cinalukast [Usan-Inn]

Used in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD₄) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Cinalukast [Usan-Inn] inhibits the actions of LTD₄ at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.

Additional information about Cinalukast [Usan-Inn]

Cinalukast [Usan-Inn] Indication

For Protection against second- phase inflamation in exercise-induced bronchoconstriction and Asthma.

Mechanism Of Action

Binds to the cysteinyl leukotriene receptor. The cysteinyl leukotrienes (LTC4, LTD₄, LTE4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene receptors (CysLT) found in the human airway. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.

Generic Name

Cinalukast

Drug Category

Antiarrhythmic Agents

Drug Type

Small Molecule; Approved

Other Brand Names containing Cinalukast

Cinalukast [Usan-Inn];

Chemical IUPAC Name

4-[[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl]amino]-2,2-diethyl-4-oxobutanoic acid

Chemical Formula

C23H28N2O3S

Organisms Affected

Humans and other mammals